Expression of Immune Response Markers in Arab Patients With Lung Cancer

PURPOSE: Programmed death-ligand 1 (PD-L1) is a marker for checkpoint inhibitor use in the management of solid tumors, especially in non–small-cell lung cancer (NSCLC). Our study was aimed at determining the patterns of PD-L1 expression and cluster of differentiation 8 (CD8) immunostains in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Jazieh, Abdul Rahman, Bounedjar, Adda, Bamefleh, Hanaa, Alfayea, Turki, Almaghraby, Hatim Q., Belarabi, Ayed, Ouahioune, Wahiba, Derbouz, Zoubir, Alkaiyat, Mohammad, Alkattan, Khaled, Damlaj, Moussab, Khalbuss, Walid E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
Special Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456317/
https://www.ncbi.nlm.nih.gov/pubmed/32749860
http://dx.doi.org/10.1200/GO.20.00107

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456317/
https://www.ncbi.nlm.nih.gov/pubmed/32749860
http://dx.doi.org/10.1200/GO.20.00107

Ejemplares similares